France invests a significant portion of its wealth in healthcare, ranking fourth globally with 11.8% of its GDP allocated to this sector, projected at €353 billion for 2025. This expenditure supports health outcomes generally above the OECD average, particularly in curative care. However, improvements are still possible in prevention and access to care, with waiting times being a relatively frequent reason for renunciation compared to European peers.
Over the past decade, healthcare spending has seen notable growth, accelerating since 2019 (+4.4% annually). This trend is expected to continue, fueled by an aging population, technological advancements offering new treatments, and rising living standards. Projections indicate that spending on healthcare and medical goods will reach 9.7% of GDP in 2035, up from 8.9% in 2025.
This upward trajectory of healthcare spending, while linked to structural evolutions, poses a major challenge for the system's financial sustainability and necessitates trade-offs with other public expenditure areas. Three main levers are identified to improve the quality and accessibility of care while controlling costs long-term: strengthening prevention to reduce avoidable care, increasing efficiency to optimize public spending impact, and implementing adequate regulation to preserve the economic balance of health as a collective good.
The distribution of financial burden between mandatory health insurance, complementary providers, and households is also a central issue. Currently, French insured individuals cover 10% of total healthcare spending, a share that has decreased since 2019 due to increased public coverage. This proportion is lower than in most neighboring countries, such as Germany (11%), the United Kingdom (14%), and Spain (20%).




